1. New GVHD Group on LLS Community!

    We have heard from you that there is a need for a group devoted to those who live with graft vs. host disease (GVHD). If you are living with GVHD, please make sure to click "Groups" on your top menu bar, and "Follow" the new GVHD group! GVHD affects individuals who have undergone an allogeneic or reduced-intensity allogeneic stem cell transplant. GVHD develops when the donor's immune cells mistakenly attack the patient's normal cells. GVHD can be acute, occurring soon after the transplant...

    Read More
  2. CAR-T Immunotherapy Showing Positive Results

    This week, positive data from a Kite Pharma CAR-T immunotherapy clinical trial was released showing that more than one-third of refractory aggressive non-Hodgkin lymphoma (NHL) patients in the study showed no signs of the disease after six months. Since 2015, The Leukemia & Lymphoma Society has been funding this study through its collaboration with Kite Pharma, a biotechnology company focused on immunotherapy. In this therapy, immune T-cells are removed from the patient’s body, an...

    Read More
  3. Choosing Treatment for Polycythemia Vera (PV)

    MPN expert Dr. Srdan Verstovsek from The University of Texas MD Anderson Cancer Center explains how doctors assess patients with polycthemia vera (PV) and determine the best treatment for each individual.

    Read More